<DOC>
	<DOCNO>NCT00526058</DOCNO>
	<brief_summary>The primary objective study demonstrate performance modify Plasmat® Futura H.E.L.P . Apheresis System non-inferior current FDA approve Plasmat® Secura H.E.L.P Apheresis System use approve indication acute reduction LDL-cholesterol plasma population diet ineffective maximum drug therapy either ineffective tolerate .</brief_summary>
	<brief_title>( H.E.L.P . ) Apheresis Therapy Compare Reduction LDL ( Low Density Lipoprotein ) Cholesterol</brief_title>
	<detailed_description>The primary study endpoint change percent measurement pre-to-post apheresis LDL measurement approve H.E.L.P . system modify H.E.L.P . system . The secondary study endpoint clinical lab profile device parameter analyze specific time point throughout study .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Subject 25 70 year age ( inclusive ) time randomization . Subject appropriate candidate H.E.L.P . apheresis treatment hypercholesterolemia accord current Plasmat® Secura approval criterion . Subject receive minimum two consecutive bimonthly* H.E.L.P . apheresis treatment use Plasmat® Secura apheresis system &gt; 30 day prior screen visit . Subject willing maintain cholesterol lower dietary drug therapy prescribe course study . Subject willing able provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) Waiver . Sterile , postmenopausal , use acceptable birth control duration study . Acceptable birth control define vasectomize , postmenopausal , sterile partner ; ongoing use approve hormonal contraceptive , barrier method , intrauterine device ; abstinence . Every 14 day ( ±2 day ) A History know sensitivity heparin ethylene oxide . A history hemorrhagic diathesis , bleeding/clotting disorder , thrombocytopenia ( defined platelet count &lt; 150 x109/L ) , use heparin would cause excessive uncontrolled anticoagulation adequate anticoagulation safely achieve ( ie. , hemophilia , recent surgery , acute internal bleeding , gastrointestinal ulcer ) . Females pregnant lactating . Subjects &lt; 106 lb . &lt; 48.2 kg body weight ; whose weight &gt; 1.5 time ideal weight . Certain cardiac impairment congestive heart failure , major arrhythmia , diastolic blood pressure great 100 mm/Hg two separate occasion least 24 hour apart . Renal insufficiency define creatinine great &gt; 2.0 mg/dlL dependent upon renal dialysis . Untreated hypothyroidism ; uncontrolled diabetes mellitus ; fast triglyceride &gt; 500 mg/dL . Serious systemic disease ( e.g. , advanced neoplasm , acute hepatitis ) include Immune system suppression compromise , could preclude survival study completion . History stroke within 6 month screen visit . Received thrombolytic treatment &lt; 7 day screening.visit . Taken require prohibit treatment &lt; 30 day prior Screening Visit , require prohibit treatment anytime course study . Neutropenia ( neutrophil count &lt; 0.5 x109/L ) . History liver disease serum ALT and/or AST &gt; 2X upper limit normal range . History dementia . History anemia ( value outside low normal range ) . acetyl salicylic acid ( ASA ) &gt; 325 mg/day . Subject currently enrol another investigational study ( apply PMS Secura device ) . Subject medical condition opinion investigator might put subject risk interfere his/her participation . Subject unwilling unable comply protocol cooperate fully investigator site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Heparin</keyword>
	<keyword>Extracorporeal</keyword>
	<keyword>Low Density Lipo-Protein ( LDL ) Cholesterol</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Device</keyword>
</DOC>